Tumor cells exploit immune checkpoints to suppress T-cell activity, notably through receptors such as programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4) [94,95]. Here, PDCD1 is linked to neoplasm.